TP53 and prostate carcinoma: However, in studies to determine the ability of the imidazopyridines to stabilize p53 expression in three different prostate cancer cell lines (22Rv.1 LNCaP, LAPC-4), none of the compounds strongly stabilized p53 (Supplementary Fig. S5A).